Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$9.82 USD
-0.41 (-4.01%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $9.98 +0.16 (1.63%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
DTIL 9.82 -0.41(-4.01%)
Will DTIL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DTIL
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Other News for DTIL
TG Therapeutics: The Cloud Over Briumvi
Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Precision BioSciences: Strategic Independence and Promising Gene Editing Pipeline Fuel Buy Rating
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics